NEW YORK (GenomeWeb) – Twist Bioscience announced today that it has raised $33 million in private financing. To date, the company has raised $166 million.
"We welcome the additional equity capital to further accelerate growth of the core gene synthesis business, as well as pharmaceutical discovery and data storage vertical strategies," Twist CEO Emily Leproust said in a statement.
Twist offers synthetic DNA manufacturing services for genes, oligonucleotide pools, and variant libraries, and is developing methods to use DNA for data storage. The company is currently involved in a lawsuit with Agilent Technologies, which alleges that Twist and certain executives stole genomics technology. Twist has denied the charges.